https://www.selleckchem.com/pr....oducts/ceftaroline-f
We found that patients using corticosteroids had reduced OSs (pooled HR, 1.82; 95% CI, 1.51-2.18) and PFSs (pooled HR, 1.69; 95% CI, 1.41-2.04) than the patients not using corticosteroids. We identified significant heterogeneity and publication bias for both the outcomes. However, the sensitivity analysis revealed that the estimates were robust to the individual study effects. Our findings suggest that corticosteroids significantly reduce the OS and PFS of patients with NSCLC under ICI therapy. Hence, clinicians and oncologi
Like
Comment
Share
